NEWSWIRETODAY Press Release& Newswire Distribution | HOME
MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
Written by / Agency / Source: Frost & Sullivan
Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Advances in Diagnostic Tests Promote a More Targeted Approach to Treatment of Systemic Fungal Infections Finds Frost & Sullivan - With fast-paced advancements in technology, the number of patients diagnosed with systemic fungal infections (SFIs) is expected to increase steadily over the next five years
Advances in Diagnostic Tests Promote a More Targeted Approach to Treatment of Systemic Fungal Infections Finds Frost & Sullivan

 

NewswireToday - /newswire/ - Mumbai, India, 2010/02/10 - With fast-paced advancements in technology, the number of patients diagnosed with systemic fungal infections (SFIs) is expected to increase steadily over the next five years.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Alongside this development, a high premium on products that are capable of tackling emergent, problematic pathogens will also contribute to changing market dynamics. Estimates reveal that the global prevalence of SFI has risen to 4 for every 1,000 of the global population.

The high incidence of SFI over the years is attributed to the widespread use of broad–spectrum antibiotics, which reduce non–pathogenic bacterial populations that compete with fungi, and the growing number of persons with compromised immune systems caused by acquired immunodeficiency syndrome (AIDS), immunosuppressant drugs, and chemotherapy agents.

New analysis from Frost & Sullivan (pharma.frost.com), Systemic Fungal Infection Therapeutics Market - India, finds that local manufacturers are expected to continue to dominate the SFI drug market due to their output of generic medication, although multinationals are trying to gain a foothold through the introduction of newly patented medication.

If you are interested in more information on this study, please send an email to Anish Charles/ Nimisha Iyer, Corporate Communications, at anishc[.]frost.com/ niyer[.]frost.com, with your full name, company name, title, telephone number, company email address, company website, city, state and country.

"Early diagnosis of systemic fungal infections has been shown to be critical to treatment outcome," says Frost & Sullivan Program Manager Carole Gaffud. "Advances in diagnostic capabilities are paving the way for more increased usage of targeted therapy for systemic fungal infections; this is reflected in the growing proportion of patients treated definitively in the last five years."

Although key therapeutics have been in the market to treat the most causative pathogen (Candida Albicans), there is still an unmet need to treat more resistant pathogens such as Aspergillus. Despite the advent of more advanced molecular diagnostic technologies, physicians in India continue to use empiric and prophylactic therapies to treat SFI. As more resistant pathogens in systemic fungal infections emerge, treatment is centered on ensuring that the right treatment is administered to the patient.

"Doctors are under pressure to ensure that they identify the most suitable mode of treatment, based on universal criteria, such as risk factors, clinical, radiological, microbiological or other diagnostic evidence," says Gaffud. "The task is made easier for physicians with the growing availability of non-microbiologic and clinical diagnostic techniques, such as Platelia, Fungitell and PNA FISH, to identify the onset of infection."

This places greater emphasis on matching antifungal choice to pathogen susceptibility, increasing the demand for rapid typing of pathogens to ensure informed, targeted drug choices. Consequently, there would be a reduction in the use of prophylaxis in the 'at-risk' patient group and the empiric therapy in, for example, patients in this group with a persistent fever or other suggestive symptoms.

Considering the relatively niche nature of SFI, it is vital for key participants to differentiate their products, especially as advances in diagnostic techniques bring about a restriction of prescriptions to specific therapeutic uses. Therapeutics are shifting away from broad and empiric indications, and pharmaceutical manufacturers need to position their products to address more specific indications defined by pathogen species (and sub species) and patient populations, rather than a broad spectrum. This gives room for a higher degree of differentiation, protecting the specific drug from generic erosion in the future.

The changing epidemiology of causative pathogens has caused the effectiveness of existing therapeutic options to decline. In such a scenario, pharmaceutical manufacturers need to develop drugs that address specific indications, in terms of pathogen coverage and patient groups, that is, solid organ transplant, cancer, neonates, human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS), and surgical patients.

Systemic Fungal Infection Therapeutics Market - India is part of the Pharmaceuticals & Biotechnology Growth Partnership Service program, which also includes research in the following markets: The Systemic Fungal Infection Therapeutics Market in Malaysia, The Systemic Fungal Infection Therapeutics Market in the Philippines, The Systemic Fungal Infection Therapeutics Market in South Korea, The Systemic Fungal Infection Therapeutics Market in Hong Kong, The Systemic Fungal Infection Therapeutics Market in Australia, The Systemic Fungal Infection Therapeutics Market in Taiwan, The Systemic Fungal Infection Therapeutics Market in Singapore, and The Systemic Fungal Infection Therapeutics Market in Thailand. All research services included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants.

About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best-in-class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best-practice models to drive the generation, evaluation, and implementation of powerful growth strategies. Frost & Sullivan leverages over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from 40 offices on six continents.

Systemic Fungal Infection Therapeutics Market - India / P25E

Contact:
Tanu Chopra
Corporate Communications – South Asia and Middle East
P: +91 22 4001 3437
F: +91 22 2832 4713
E: tanu.chopra[.]frost.com.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Frost & Sullivan

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+]  / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma / BioTech / Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Advances in Diagnostic Tests Promote a More Targeted Approach to Treatment of Systemic Fungal Infections Finds Frost & Sullivan

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
Publisher Contact: Anish Charles / Nimisha Iyer 
+91.22.4001 3419 / +91 98200 50519 anishc[.]frost.com/ niyer[.]frost.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Pharma / BioTech / Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Frost & Sullivan / Company Profile


Read Pharma / BioTech / Nutrition Most Recent Related Newswires:

Ipsen Adds Another Program into its Pre-clinical R&D Oncology Pipeline through An Exclusive Worldwide Collaboration with Accent Therapeutics
Evaxion Biotech Lauded by Frost & Sullivan for Helping Develop Highly Targeted Therapies with its AI Immunology Platforms
Kyowa Hakko Acclaimed by Frost & Sullivan for its Non-GMO, Allergen-free, Immune Support Paraprobiotic Ingredient, IMMUSE™
DSM to Acquire First Choice Ingredients to Accelerate Growth in Food and Beverage
STEMCELL Technologies Launches Human Pluripotent Stem Cell Characterization and Banking Services in Partnership with WiCell
Biocon Selects TrackWise to Enable Enterprise Quality Management Across Global Biopharmaceutical Operations
STEMCELL Technologies and Hubrecht Organoid Technology to Partner on Non-Oncology Organoid Drug Screening Services
Ipsen and Exicure Enter into Exclusive Collaboration Targeting Rare Neurodegenerative Disorders
Ipsen Strengthens its Pre-clinical Oncology Pipeline with An Exclusive Worldwide-collaboration with BAKX Therapeutics, Inc. for BKX-001
Pharma and Biotech to Highly Invest in RNA Therapeutics to Expedite Research & Development across the Globe Finds Frost & Sullivan
Parexel Commended by Frost & Sullivan for Developing a Flexible and Agile Delivery Model to Improve Clinical Trial Outcome
Ipsen and IRLAB Enter Exclusive Worldwide Licensing Agreement Aimed to Improve the Lives of People Living with Parkinson’s Disease
Exelixis and Ipsen Announce Cabozantinib in Combination with An Immune Checkpoint Inhibitor Significantly Improved Progression
Ipsen Opts-in to Join Exelixis with Ongoing Development of Cabometyx® for People Living with A Form of Thyroid Cancer
Antibiotic Alternatives Stimulate New Product Development in Global Animal Feed Ingredient Market Finds Frost & Sullivan

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  JobsWare.com

Visit  BizJobs.com





 
  ©2021 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are proudly NOT affiliated with USA TODAY (usatoday.com)